I. De Meester

发表

B. Bauvois, C. Antczak, I. De Meester, 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning

I. De Meester, S. Korom, T. Wekerle, 2012, Experimental hematology.

Levels and profiles of PCBs and OCPs in marine benthic species from the Belgian North Sea and the Western Scheldt Estuary.

A. Covaci, P. Schepens, I. De Meester, 2004, Marine pollution bulletin.

The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model

A. Lambeir, I. De Meester, M. Berg, 2021, Frontiers in Pharmacology.

Local Colonic Administration of a Serine Protease Inhibitor Improves Post-Inflammatory Visceral Hypersensitivity in Rats

I. De Meester, M. Berg, Tim Boogaerts, 2021, Pharmaceutics.

A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation

L. Moons, A. Lambeir, I. De Meester, 2020, Scientific Reports.

Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post‐inflammatory rat model for irritable bowel syndrome

A. Lambeir, I. De Meester, J. Timmermans, 2018, British journal of pharmacology.

Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV.

P. Proost, A. Lambeir, I. De Meester, 2003, Advances in experimental medicine and biology.

Kinetic study of the processing by dipeptidyl‐peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion

C. Durinx, P. Proost, A. Lambeir, 2001, FEBS letters.

Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling.

V. Fülöp, W. Luyten, A. Lambeir, 2017, European journal of medicinal chemistry.

Expression, purification and preliminary crystallographic analysis of dipeptidyl peptidase IV from Porphyromonas gingivalis.

V. Fülöp, A. Lambeir, I. De Meester, 2004, Acta crystallographica. Section D, Biological crystallography.

Prolyl Carboxypeptidase Mediates the C-Terminal Cleavage of (Pyr)-Apelin-13 in Human Umbilical Vein and Aortic Endothelial Cells

A. Lambeir, I. De Meester, I. Pintelon, 2021, International journal of molecular sciences.

Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4.

W. Paulus, G. D. De Keulenaer, W. Linke, 2014, Cardiovascular research.

Lowered Serum dipeptidyl peptidase IV activity in patients with anorexia and bulimia nervosa

M. Maj, C. Durinx, I. De Meester, 2000, European Archives of Psychiatry and Clinical Neuroscience.

Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators

F. Rösch, I. De Meester, S. Staelens, 2020, EJNMMI Radiopharmacy and Chemistry.

Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP).

Ruth Geiss-Friedlander, A. Lambeir, I. De Meester, 2019, ACS medicinal chemistry letters.

Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.

A. Lambeir, I. De Meester, L. Maes, 2013, ACS medicinal chemistry letters.

Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides.

E. Bosmans, C. Durinx, A. Lambeir, 2000, European journal of biochemistry.

DPP8/DPP9 inhibition elicits canonical Nlrp1b inflammasome hallmarks in murine macrophages

Ruth Geiss-Friedlander, A. Lambeir, I. De Meester, 2019, Life Science Alliance.

Quantification of Vaccine-induced Antipertussis Toxin Secretory IgA Antibodies in Breast Milk: Comparison of Different Vaccination Strategies in Women

P. van Damme, I. De Meester, E. Leuridan, 2015, The Pediatric infectious disease journal.

The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis

A. Lambeir, I. De Meester, L. Baerts, 2015, Front. Immunol..

Dipeptidyl peptidase II (DPPII), a review.

I. De Meester, S. Scharpe, M. Maes, 2007, Clinica chimica acta; international journal of clinical chemistry.

Development of potent and selective dipeptidyl peptidase II inhibitors.

A. Lambeir, B. Bauvois, I. De Meester, 2002, Bioorganic & Medicinal Chemistry Letters.

Antibody binding profile of purified and cell-bound CD26. Designation of BT5/9 and TA5.9 to the CD26 cluster.

G. Vanhoof, E. Bosmans, G. Vanham, 1993, Immunobiology.

Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes.

G. Vanhoof, I. De Meester, H. Demuth, 1992, Clinica chimica acta; international journal of clinical chemistry.

Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form.

A. Lambeir, I. De Meester, J. Ketelslegers, 2006, Clinical chemistry.

Prolyl carboxypeptidase activity in the circulation and its correlation with body weight and adipose tissue in lean and obese subjects

H. Noels, P. Venge, A. Lambeir, 2018, PloS one.

Validation of a specific prolylcarboxypeptidase activity assay and its suitability for plasma and serum measurements.

A. Lambeir, I. De Meester, P. Van der Veken, 2013, Analytical biochemistry.

The expression of proline-specific enzymes in the human lung.

D. Adriaensen, A. Lambeir, I. De Meester, 2017, Annals of translational medicine.

The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice

I. De Meester, D. Schrijvers, G. D. De Meyer, 2015, Inflammation.

Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).

A. Lambeir, I. De Meester, L. Maes, 2014, Journal of medicinal chemistry.

DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.

P. D’Haese, I. De Meester, A. Verhulst, 2014, American journal of physiology. Endocrinology and metabolism.

Potential impact of sitagliptin on collagen-derived dipeptides in diabetic osteoporosis.

W. Maho, A. Covaci, I. De Meester, 2015, Pharmacological research.

Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions

H. Noels, J. Jankowski, N. Marx, 2020, Arteriosclerosis, thrombosis, and vascular biology.

Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators

F. Rösch, I. De Meester, S. Staelens, 2020, EJNMMI Radiopharmacy and Chemistry.

Distribution of Prolyl Oligopeptidase in Human Peripheral Tissues and Body Fluids

G. Vanhoof, I. De Meester, S. Scharpe, 1996, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

Assay of dipeptidyl peptidase IV in serum by fluorometry of 4-methoxy-2-naphthylamine.

G. Vanhoof, I. De Meester, S. Scharpe, 1988, Clinical chemistry.

Proteolytic Cleavage of Bioactive Peptides and Protease-Activated Receptors in Acute and Post-Colitis

P. Hulpiau, H. Koistinen, U. Stenman, 2021, International journal of molecular sciences.

Components of biological variation in prolyl endopeptidase and dipeptidyl-peptidase IV activity in plasma of healthy subjects.

H. Neels, M. Maes, I. De Meester, 1994, Clinical chemistry.

In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma.

A. Lambeir, I. De Meester, P. Budde, 2009, Biochemical pharmacology.

Peroxynitrite Exposure of CXCL12 Impairs Monocyte, Lymphocyte and Endothelial Cell Chemotaxis, Lymphocyte Extravasation in vivo and Anti-HIV-1 Activity

M. Rosenkilde, G. Opdenakker, P. Proost, 2018, Front. Immunol..

Kinetic Study of Neuropeptide Y (NPY) Proteolysis in Blood and Identification of NPY3–35

K. Abid, I. De Meester, R. Stöcklin, 2009, The Journal of Biological Chemistry.

A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro.

P. Proost, A. Lambeir, I. De Meester, 2002, Biochemical pharmacology.

CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3.

E. De Clercq, M. Parmentier, G. Opdenakker, 1999, Journal of immunology.

Processing by CD26/dipeptidyl‐peptidase IV reduces the chemotactic and anti‐HIV‐1 activity of stromal‐cell‐derived factor‐1α

E. De Clercq, C. Durinx, P. Proost, 1998, FEBS letters.

Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26/dipeptidyl peptidase IV (EC 3.4.14.5).

G. Vanhoof, I. De Meester, S. Scharpe, 1996, Journal of immunological methods.

Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside

A. Lambeir, I. De Meester, J. Bartunek, 2009, Clinical chemistry and laboratory medicine.

The role of CD26/DPP IV in chemokine processing.

P. Proost, I. De Meester, S. Sozzani, 1999, Chemical immunology.

Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries

G. D. De Keulenaer, I. De Meester, G. D. De Meyer, 2011, Biological chemistry.

Altered CD4+ T cell immunity in nurses occupationally exposed to viral pathogens

P. van Damme, A. Souquette, P. Thomas, 2018, Clinical and experimental immunology.

Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases.

A. Lambeir, I. De Meester, P. Van der Veken, 2005, Journal of medicinal chemistry.

CD26/dipeptidylpeptidase IV-targeted therapy of acute lung rejection in rats.

I. De Meester, P. Vogt, S. Korom, 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Circulating Stromal Cell-Derived Factor 1α Levels in Heart Failure: A Matter of Proper Sampling

I. De Meester, P. Van der Veken, M. Vanderheyden, 2015, PloS one.

Possible mechanisms for brain natriuretic peptide resistance in heart failure with a focus on interspecies differences and canine BNP biology.

I. De Meester, M. Vanderheyden, N. Gomez, 2012, Veterinary journal.

Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme.

I. De Meester, G. Mulder, J. Balzarini, 2013, European journal of medicinal chemistry.

The Effect of Serine Protease Inhibitors on Visceral Pain in Different Rodent Models With an Intestinal Insult

P. Pasricha, I. De Meester, Liansheng Liu, 2022, Frontiers in Pharmacology.

CD26, let it cut or cut it down.

I. De Meester, J. Van Damme, S. Korom, 1999, Immunology today.

Breastfeeding after maternal immunisation during pregnancy: providing immunological protection to the newborn: a review.

P. van Damme, I. De Meester, E. Leuridan, 2014, Vaccine.

Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?

Xin Chen, A. Lambeir, I. De Meester, 2011, Journal of medicinal chemistry.

Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues.

I. De Meester, J. Balzarini, M. Camarasa, 2011, Journal of medicinal chemistry.

DPP4 inhibitors for diabetes--what next?

A. Lambeir, I. De Meester, S. Scharpe, 2008, Biochemical pharmacology.

Development and evaluation of peptide-based prolyl oligopeptidase inhibitors--introduction of N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine as a lead in inhibitor design.

G. Vanhoof, I. De Meester, D. Tourwé, 1997, European journal of biochemistry.

The Effect of Organ-Specific CD26/DPP IV Enzymatic Activity Inhibitor-Preconditioning on Acute Pulmonary Allograft Rejection

I. De Meester, S. Korom, W. Weder, 2009, Transplantation.

Primary Graft Dysfunction in Lung Transplantation: The Role of CD26/Dipeptidylpeptidase IV and Vasoactive Intestinal Peptide

I. De Meester, S. Korom, W. Weder, 2009, Transplantation.

Intragraft DPP IV inhibition attenuates post-transplant pulmonary ischemia/reperfusion injury after extended ischemia.

I. De Meester, S. Korom, W. Weder, 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

CD26 expression and enzymatic activity in recipients of kidney allografts.

J. Kupiec-Weglinski, I. De Meester, H. Grimm, 2002, Transplantation proceedings.

Specific inhibition of CD26/DPP IV enzymatic activity in allograft recipients: effects on humoral immunity.

C. Durinx, J. Kupiec-Weglinski, I. De Meester, 1999, Transplantation proceedings.

Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients.

J. Kupiec-Weglinski, I. De Meester, M. Sayegh, 1997, Transplantation.

Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects.

G. Vanhoof, E. Bosmans, J. Ceuppens, 1993, Journal of acquired immune deficiency syndromes.

CD26 costimulatory blockade improves lung allograft rejection and is associated with enhanced interleukin-10 expression.

I. Yoshino, I. De Meester, W. Weder, 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.

E. De Clercq, P. Proost, I. De Meester, 1998, Antiviral research.

Regulation of intestinal permeability: The role of proteases

A. Lambeir, I. De Meester, B. D. De Winter, 2017, World journal of gastroenterology.

Importance of biofilm formation and dipeptidyl peptidase IV for the pathogenicity of clinical Porphyromonas gingivalis isolates.

W. Teughels, M. Quirynen, A. Lambeir, 2014, Pathogens and disease.

Glycosaminoglycans Regulate CXCR3 Ligands at Distinct Levels: Protection against Processing by Dipeptidyl Peptidase IV/CD26 and Interference with Receptor Signaling

P. Proost, I. De Meester, M. Teixeira, 2017, International journal of molecular sciences.

Truncation of Macrophage-derived Chemokine by CD26/ Dipeptidyl-Peptidase IV beyond Its Predicted Cleavage Site Affects Chemotactic Activity and CC Chemokine Receptor 4 Interaction*

P. Allavena, G. Opdenakker, P. Proost, 1999, The Journal of Biological Chemistry.

Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).

Xin Chen, A. Lambeir, I. De Meester, 2005, Biochemical pharmacology.

Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor

Ji Ming Wang, P. Proost, I. De Meester, 1998, European journal of immunology.

Clinical Investigation of French Maritime Pine Bark Extract on Attention-Deficit Hyperactivity Disorder as compared to Methylphenidate and Placebo: Part 2: Oxidative Stress and Immunological Modulation

B. Ceulemans, D. Beysen, I. De Meester, 2022, Journal of Functional Foods.

Soluble CD26 / Dipeptidyl Peptidase IV Enhances Human Lymphocyte Proliferation In Vitro Independent of Dipeptidyl Peptidase Enzyme Activity and Adenosine Deaminase Binding

I. De Meester, C. Abbott, G. McCaughan, 2011, Scandinavian journal of immunology.

Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors.

Xin Chen, A. Lambeir, I. De Meester, 2008, Bioorganic & medicinal chemistry letters.

Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.

Xin Chen, A. Lambeir, I. De Meester, 2008, Bioorganic & medicinal chemistry letters.

Dipeptidyl peptidase 8/9‐like activity in human leukocytes

Xin Chen, A. Lambeir, I. De Meester, 2007, Journal of leukocyte biology.

DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury.

I. De Meester, N. Hermans, V. Matheeussen, 2012, American journal of physiology. Renal physiology.

Natural substrates of dipeptidyl peptidase IV.

C. Durinx, P. Proost, I. De Meester, 2000, Advances in experimental medicine and biology.

Study of the enzymatic degradation of vasostatin I and II and their precursor chromogranin A by dipeptidyl peptidase IV using high-performance liquid chromatography/electrospray mass spectrometry.

M. Claeys, I. De Meester, L. Dillen, 1999, Journal of mass spectrometry : JMS.

Dipeptidyl peptidases and related proteins: multifaceted markers and therapeutic targets

A. Lambeir, I. De Meester, S. Scharpe, 2009, Clinical chemistry and laboratory medicine.

Effect of heart failure on dipeptidyl peptidase IV activity in plasma of dogs.

I. De Meester, V. Matheeussen, C. Clercx, 2012, Journal of veterinary internal medicine.

CD26/DPP IV in experimental and clinical organ transplantation.

I. De Meester, S. Korom, K. Schwemmle, 2003, Advances in experimental medicine and biology.

CD26/DPP IV-mediated modulation of acute rejection.

H. Volk, J. Kupiec-Weglinski, I. De Meester, 1999, Transplantation proceedings.

In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (Prodipine).

I. De Meester, G. D. De Meyer, A. Haemers, 1997, Biochemical pharmacology.

Binding of adenosine deaminase to the lymphocyte surface via CD26

G. Vanhoof, E. Bosmans, G. Vanham, 1994, European journal of immunology.

Kininase activity in human platelets: cleavage of the Arg1-Pro2 bond of bradykinin by aminopeptidase P.

G. Vanhoof, I. De Meester, S. Scharpe, 1992, Biochemical pharmacology.

Distribution of Proline-Specific Aminopeptidases in Human Tissues and Body Fluids

G. Vanhoof, I. De Meester, S. Scharpe, 1992, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

Aminopeptidase P and dipeptidyl peptidase IV activity in human leukocytes and in stimulated lymphocytes.

G. Vanhoof, I. De Meester, S. Scharpe, 1991, Clinica chimica acta; international journal of clinical chemistry.

Exopeptidases in human platelets: an indication for proteolytic modulation of biologically active peptides.

G. Vanhoof, I. De Meester, S. Scharpe, 1991, Clinica chimica acta; international journal of clinical chemistry.

Dipeptidyl peptidase IV in human lymphocytes: molecular properties.

G. Vanhoof, I. De Meester, S. Scharpe, 1990, Biochemical Society transactions.

The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma.

A. Lambeir, I. De Meester, R. Van Elzen, 2019, Clinica chimica acta; international journal of clinical chemistry.

Costimulation of CD4+ and CD8+ T cells through CD26: The ADA‐binding epitope is not essential for complete signaling

G. Vanhoof, G. Vanham, I. De Meester, 1995, Journal of leukocyte biology.

Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV.

G. Opdenakker, P. Proost, I. De Meester, 1998, Biochemistry.

Ischemia/reperfusion injury: The role of CD26/dipeptidyl-peptidase-IV-inhibition in lung transplantation.

I. De Meester, S. Korom, W. Weder, 2006, Transplantation proceedings.

Dysregulation of the renin-angiotensin system during lung ischemia-reperfusion injury

P. V. Van Schil, A. Lambeir, I. De Meester, 2016, Experimental lung research.

Design, synthesis, and SAR of potent and selective dipeptide-derived inhibitors for dipeptidyl peptidases.

A. Lambeir, I. De Meester, P. Van der Veken, 2003, Journal of medicinal chemistry.

Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-Concept Observational Study.

I. De Meester, J. Maes, J. Mertens, 2021, Clinical therapeutics.

Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases

A. Lambeir, I. De Meester, B. D. De Winter, 2016, World journal of gastroenterology.

Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors.

A. Lambeir, I. De Meester, A. Haemers, 1999, Journal of medicinal chemistry.

Rapid parallel synthesis of dipeptide diphenyl phosphonate esters as inhibitors of dipeptidyl peptidases.

A. Lambeir, I. De Meester, P. Van der Veken, 2003, Journal of combinatorial chemistry.

Rapid parallel synthesis of dipeptide diphenyl phosphonate esters as inhibitors of dipeptidyl peptidases.

A. Lambeir, I. De Meester, P. Van der Veken, 2003, Journal of combinatorial chemistry.

Irreversible inhibition of dipeptidyl peptidase 8 by dipeptide-derived diaryl phosphonates.

Xin Chen, A. Lambeir, I. De Meester, 2007, Journal of medicinal chemistry.

In vivo effects of a potent, selective DPPII inhibitor: UAMC00039 is a possible tool for the elucidation of the physiological function of DPPII.

A. Lambeir, I. De Meester, P. Van der Veken, 2006, Advances in experimental medicine and biology.

Dipeptide-derived diphenyl phosphonate esters: mechanism-based inhibitors of dipeptidyl peptidase IV.

A. Lambeir, I. De Meester, A. Haemers, 1996, Biochimica et Biophysica Acta.

Proline motifs in peptides and their biological processing

Greet Vanhoof, G. Vanhoof, I. De Meester, 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors.

A. Lambeir, I. De Meester, V. Matheeussen, 2012, Clinica chimica acta; international journal of clinical chemistry.

Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist.

P. Proost, I. De Meester, J. Van Damme, 2000, Blood.

The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety.

E. Bosmans, H. Neels, M. Maes, 1998, Cytokine.

Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV

C. Durinx, A. Lambeir, I. De Meester, 2003, Critical reviews in clinical laboratory sciences.

Acute Ischemic Stroke Severity, Progression, and Outcome Relate to Changes in Dipeptidyl Peptidase IV and Fibroblast Activation Protein Activity

S. Engelborghs, I. De Meester, R. Brouns, 2017, Translational Stroke Research.

Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs.

I. De Meester, J. Balzarini, M. Camarasa, 2010, Journal of medicinal chemistry.

Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach.

I. De Meester, J. Balzarini, M. Camarasa, 2006, Journal of medicinal chemistry.

The purification, characterization and analysis of primary and secondary-structure of prolyl oligopeptidase from human lymphocytes. Evidence that the enzyme belongs to the alpha/beta hydrolase fold family.

G. Vriend, G. Vanhoof, I. De Meester, 1995, European journal of biochemistry.

CD26/DPP4 - a potential biomarker and target for cancer therapy.

I. De Meester, W. Jungraithmayr, G. Vliegen, 2019, Pharmacology & therapeutics.

Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods.

C. Boeckx, B. Neyns, I. De Meester, 2018, Archives of pathology & laboratory medicine.

Proteases and their inhibitors: today and tomorrow.

G. Vriend, G. Vanhoof, I. De Meester, 1991, Biochimie.

Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice

Yoshito Yamada, Wolfgang Jungraithmayr, Walter Weder, 2015, Clinical & Experimental Metastasis.

Dipeptidyl peptidase 9 (DPP9) from bovine testes: identification and characterization as the short form by mass spectrometry.

Y. Guisez, A. Lambeir, I. De Meester, 2010, Biochimica et biophysica acta.

Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury.

I. De Meester, V. Matheeussen, W. Jungraithmayr, 2012, Pharmacology & therapeutics.

Chemically diverse activity-based probes with unexpected inhibitory mechanisms targeting trypsin-like serine proteases

G. Boeckxstaens, A. Lambeir, I. De Meester, 2023, Frontiers in Chemistry.

Stromal populations and fibrosis in human long-term bone marrow cultures.

G. Vanhoof, Z. Berneman, D. V. van Bockstaele, 1991, Leukemia.

Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.

A. Lambeir, I. De Meester, P. Van der Veken, 2012, Bioorganic & medicinal chemistry letters.

Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system

C. Boeckx, B. Neyns, I. De Meester, 2017, Histopathology.

The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity

I. De Meester, W. Weder, W. Jungraithmayr, 2019, Carcinogenesis.

Dipeptidyl peptidase II and leukocyte cell death.

A. Lambeir, I. De Meester, D. Schrijvers, 2006, Biochemical pharmacology.

Kinetic Investigation of Chemokine Truncation by CD26/Dipeptidyl Peptidase IV Reveals a Striking Selectivity within the Chemokine Family*

C. Durinx, P. Proost, A. Lambeir, 2001, The Journal of Biological Chemistry.

Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

B. Bauvois, I. De Meester, Delphine Garnier, 2022, Cancers.

Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia

S. Bonaccorso, I. De Meester, M. Biondi, 1998, Psychological Medicine.

In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi

F. Rösch, I. De Meester, P. Van der Veken, 2021, Molecules.

Peptide substrates of dipeptidyl peptidases.

A. Lambeir, I. De Meester, S. Scharpe, 2006, Advances in experimental medicine and biology.

A CD26-Controlled Cell Surface Cascade for Regulation of T Cell Motility and Chemokine Signals1

I. De Meester, K. Sundqvist, Zhiwen Liu, 2009, The Journal of Immunology.

Lower activity of serum peptidases in abstinent alcohol-dependent patients.

H. Neels, M. Maes, I. De Meester, 1999, Alcohol.

Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis

I. De Meester, S. Kumar-Singh, E. Vlieghe, 2022, Journal of clinical medicine.

Cloning and sequence analysis of the gene encoding human lymphocyte prolyl endopeptidase.

G Vriend, G. Vriend, C. van Broeckhoven, 1994, Gene.

Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2)

P. Jorens, A. Lambeir, I. De Meester, 2020, PloS one.

Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7).

A. Lambeir, I. De Meester, B. Leiting, 2005, The Biochemical journal.

Prolyl carboxypeptidase purified from human placenta: its characterization and identification as an apelin-cleaving enzyme.

A. Lambeir, I. De Meester, R. Van Elzen, 2016, Biochimica et biophysica acta.

A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma.

J. V. Van Beeumen, B. Devreese, A. Lambeir, 1997, Biochimica et biophysica acta.

Human lymphocyte X-prolyl aminopeptidase (aminopeptidase P)-like protein. A new member of the proline peptidase family?

G. Vanhoof, L. Juliano, M. Juliano, 1997, Advances in experimental medicine and biology.

Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV

Dominique Schols, Paul Proost, E. De Clercq, 1998, The Journal of Biological Chemistry.

A sensitive method for the assay of serum prolyl endopeptidase.

G. Vanhoof, I. De Meester, S. Scharpe, 1992, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics

I. De Meester, P. Van der Veken, C. Bal, 2023, Cancers.

CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation.

I. De Meester, V. Matheeussen, W. Weder, 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy.

V. Fülöp, V. Baekelandt, A. Lambeir, 2012, Journal of medicinal chemistry.

Corrigendum to: Kinetic study of the processing by dipeptidyl‐peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion (FEBS 25376)

C. Durinx, P. Proost, A. Lambeir, 2002 .

The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice

I. De Meester, D. Schrijvers, G. D. De Meyer, 2016, Inflammation.

Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients

I. De Meester, S. Kumar-Singh, E. Vlieghe, 2022, Clinica Chimica Acta.

Disturbances in dexamethasone suppression test and lower availability of L-tryptophan and tyrosine in early puerperium and in women under contraceptive therapy.

Y. Jacquemyn, I. De Meester, S. Scharpe, 1992, Journal of psychosomatic research.

Isolation and identification of naturally modified C-C chemokines MCP-1, MCP-2 and RANTES: effects of posttranslational modifications on receptor usage, chemotactic and anti-HIV-1 activity.

E. De Clercq, P. Proost, A. Lambeir, 1998, European Cytokine Network.

Exploration of the active site of dipeptidyl peptidase IV from Porphyromonas gingivalis. Comparison with the human enzyme.

V. Fülöp, A. Lambeir, I. De Meester, 2003, Advances in experimental medicine and biology.

Anti‐inflammatory effects on ischemia/reperfusion‐injured lung transplants by the cluster of differentiation 26/dipeptidylpeptidase 4 (CD26/DPP4) inhibitor vildagliptin

I. De Meester, W. Weder, I. Inci, 2017, The Journal of thoracic and cardiovascular surgery.

The Chemokine-Based Peptide, CXCL9(74-103), Inhibits Angiogenesis by Blocking Heparan Sulfate Proteoglycan-Mediated Signaling of Multiple Endothelial Growth Factors

P. Carmeliet, P. Proost, I. De Meester, 2021, Cancers.

ProCPU Is Expressed by (Primary) Human Monocytes and Macrophages and Expression Differs between States of Differentiation and Activation

I. De Meester, S. Thys, D. Hendriks, 2023, International Journal of Molecular Sciences.

Vildagliptin‐Derived Dipeptidyl Peptidase 9 (DPP9) Inhibitors: Identification of a DPP8/9‐Specific Lead

I. De Meester, P. Van der Veken, K. Augustyns, 2022, ChemMedChem.

In Vitro and In Situ Activity-Based Labeling of Fibroblast Activation Protein with UAMC1110-Derived Probes

O. De Wever, A. Lambeir, I. De Meester, 2021, Frontiers in Chemistry.

Intercellular interaction between FAP fibroblasts and CD150 inflammatory monocytes mediates fibro-stenosis in Crohn’s disease

S. Vermeire, I. De Meester, A. Wolthuis, 2023, bioRxiv.

Prolyl Carboxypeptidase Activity Is Present in Human Adipose Tissue and Is Elevated in Serum of Obese Men with Type 2 Diabetes

I. De Meester, K. Verboven, K. Wouters, 2022, International Journal of Molecular Sciences.

The role of CD26/DPP IV in preservation of early pulmonary graft function.

I. De Meester, S. Korom, W. Weder, 2006, Advances in experimental medicine and biology.